Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine

Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine

Abstract Background High tumor mutational burden (TMB) was reported to predict the efficacy of immune checkpoint inhibitors (ICIs). Pembrolizumab, an anti-PD-1, received FDA-approval for the treatment of unresectable/metastatic tumors with high TMB as determined by the FoundationOne®CDx test. It rem...

Full description

Bibliographic Details
Main Authors: Célia Dupain, Tom Gutman, Elodie Girard, Choumouss Kamoun, Grégoire Marret, Zahra Castel-Ajgal, Marie-Paule Sablin, Cindy Neuzillet, Edith Borcoman, Ségolène Hescot, Céline Callens, Olfa Trabelsi-Grati, Samia Melaabi, Roseline Vibert, Samantha Antonio, Coralie Franck, Michèle Galut, Isabelle Guillou, Maral Halladjian, Yves Allory, Joanna Cyrta, Julien Romejon, Eleonore Frouin, Dominique Stoppa-Lyonnet, Jennifer Wong, Christophe Le Tourneau, Ivan Bièche, Nicolas Servant, Maud Kamal, Julien Masliah-Planchon
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Biology
Subjects:
Tumor mutational burden
Calculation
Immunotherapy
Precision medicine
Molecular Tumor Board
Online Access:https://doi.org/10.1186/s12915-024-01839-8

Internet

https://doi.org/10.1186/s12915-024-01839-8

Similar Items